SCHEMBL6929228

SCHEMBL6929228

O=C1OC(c2ccc(-c3ccc(Cl)cc3)cc2)C(O)=C1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
HTT P42858 3/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 3/20 0.43
RET P07949 1/20 0.38
KDR P35968 1/20 0.38
SERPINE1 P05121 1/20 0.37
AR P10275 1/20 0.37
CYP1A2 P05177 2/20 0.36
TP53 P04637 2/20 0.36
MDM2 Q00987 1/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
POLB P06746 2/20 0.36
MAOB P27338 2/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929961 1.00 ALDH1A1 (0.47) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL7567210 0.95 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL6026250 0.95 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL7567255 0.95 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL6930001 0.86 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL6931344 0.86 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL7591786 0.84 AHR (0.41) ALDH1A1KMT2AMEN1HTTLMNA
SCHEMBL6933173 0.84 AHR (0.41) ALDH1A1KMT2AMEN1HTTLMNA
SCHEMBL6929995 0.84 SRD5A2 (0.43) ALDH1A1KMT2AMEN1HTTHPGD
SCHEMBL7589372 0.84 SRD5A2 (0.43) ALDH1A1KMT2AMEN1HTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US claimed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed
EP-1246811-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS Isle of Man, Limited (GB) 2002-10-09 EP disclosed
WO-2001049671-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN, LIMITED (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones ADH1C, SRD5A2, SRD5A1 ALDH1A1 311/4885KMT2A 3901/4885MEN1 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.